Exclusive: ARCH and GV are building a large startup focused on mitochondrial diseases
ARCH Venture and GV, the venture arm of Alphabet, are building a large new company focused on mitochondrial diseases: rare genetic ones, initially, but eventually larger and more complex conditions such Alzheimer’s and Parkinson’s that are influenced by the so-called powerhouse of the cell.
The company, known as Pretzel Therapeutics, will combine a suite of different technologies, including multiple types of gene editing and small molecules meant to increase the number of healthy mitochondria in a patient. The name derives from a passing resemblance between mitochondria and pretzels. (Think warm at the pub, with mustard, not Rold Gold.)
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.